Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PARG | Q86W56 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26920565 | 0.86 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL17588940 | 0.86 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29734718 | 0.86 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL138511 | 0.84 | RXRA (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29263972 | 0.83 | ALDH1A1 (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL1141263 | 0.83 | RXRA (0.36) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL1141294 | 0.82 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29384146 | 0.81 | CYP4F2 (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL16647245 | 0.81 | CYP4F2 (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL1141310 | 0.81 | RXRA (0.36) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227480-B2 | Indazole derivative having spiro ring structure in side chain | UBE INDUSTRIES, LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227480-B2 | Indazole derivative having spiro ring structure in side chain | UBE INDUSTRIES, LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-8227480-B2 | Indazole derivative having spiro ring structure in side chain | UBE INDUSTRIES, LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20090170887-A1 | Novel indazole derivative having spiro ring structure in side chain | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170887-A1 | Novel indazole derivative having spiro ring structure in side chain | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170887-A1 | Novel indazole derivative having spiro ring structure in side chain | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-2025676-A1 | NOVEL INDAZOLE DERIVATIVE HAVING SPIRO RING STRUCTURE IN SIDE CHAIN | Ube Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170887-A1 | Novel indazole derivative having spiro ring structure in side chain | CIT, ROCK1, ROCK2 | RXRA 2061/4885RXRB 1615/4885RXRG 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.